Met Life Investment Management, LLC Pyxis Oncology, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 18,818 shares of PYXS stock, worth $71,884. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,818
Previous 13,334
41.13%
Holding current value
$71,884
Previous $44,000
56.82%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PYXS
# of Institutions
101Shares Held
28.2MCall Options Held
539KPut Options Held
54.1K-
Deep Track Capital, LP Greenwich, CT4.18MShares$16 Million0.57% of portfolio
-
Laurion Capital Management LP New York, NY3.63MShares$13.9 Million0.18% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$10.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.43MShares$9.29 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.91MShares$7.28 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $134M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...